The Philadelphia chromosome (Phi), present in >195% of chronic myelogenous leukemia (CML) patients, is a well-characterized translocation that results in a unique chimeric gene product (BCR/ABL) with transforming capability. Molecular methods utilizing the polymerase chain reaction (PCR) to detect BCR/ABL mRNA transcripts has been useful for detecting minimal residual disease (MRD) after treatment, as well as for establishing the diagnosis of CML. Amplification-based assays

Introduction
The Philadelphia chromosome (Phi) is a truncated derivative of chromosome 22 that arises through a reciprocal translocation involving the long arms of chromosomes 9 and 22 and is observed in -95% of chronic myelogenous leukemia (CML) patients. A chimeric gene, BCR/ABL, is generated through the translocation of the upstream region of the BCR gene (located on chromosome 22) to the ABL gene (located on chromosome 9). Breakpoints on chromosome 9 occur within a wide region, in >200 kilobases (kb), extending from exon 2 of ABL to a distance 5' of the entire gene. Breakpoints on chromosome 22 occur intronically clustered near the middle the BCR gene, within a five-exon region designated the major breakpoint cluster region (M-BCR). Although the DNA breakpoints within the BCR and ABL genes are variable, RNA splicing results in precise exon joining. In CML cells, this hybrid mRNA consists of BCR exon 2/ABL exon 2 (B2A2) and/or BCR exon 3/ABL exon 2 (B3A2) fusions. This 8.5-kb transcript is translated into a 210-kD protein (P210) with altered tyrosine kinase activity, which is implicated in the progression of CML [1] .
Selective amplification of the chimeric BCR/ ABL oncogene mRNA transcript using reverse transcription and the polymerase chain reaction (RT-PCR) enables faster and significantly more sensitive detection of Phi-positive cells than cytogenetic analysis or Southern blotting [2] . These alternative techniques require that Phi-positive cells comprise at least 1% of the leukocyte population for detection. RT-PCR Detection of Phi has utility as a means of monitoring patients after bone marrow transplant (BMT) for minimal residual disease (MRD). Recent studies have now demonstrated that PCR detection of Phi-positive cells is valuable in predicting disease progression for CML patients in apparent clinical remission after BMT [3] . These studies have shown that CML patients persistently positive for the BCR/ABL mRNA by RT-PCR after BMT are at significantly greater risk of relapse. Conversely, those CML patients persistently BCR/ABL negative are at a low risk of relapse. Molecular detection of Phipositive cells can provide information on early relapse although patients remain in cytogenetic and hematologic remission. RT-PCR detection of Phi is also useful in establishing the diagnosis of CML.
Many investigators have reported the use of PCR-based methodologies to monitor Phi-positive cell populations after BMT [4--10] . A major obstacle surrounding the routine use of PCR for detecting MRD is reproducibility and the potential for false positive and false negative assays. To overcome these problems, we have developed, and describe here, an assay system in which template quality, assay components, and assay sensitivity are internally controlled.
Materials and Methods
RNA Preparation
Total cellular RNA was prepared from peripheral blood, peripheral blood buffy coats, or peripheral blood mononuclear cells isolated by FicollHypaque, or cultured B cells and K562 (Phipositive) cells. Cells were either viably frozen or directly added to 4 M of guanidinium isothiocyanate. RNA was prepared from 3-5 million cells as previously described with minor modifications [I 1]. Electrophoretic separation of sample RNA preparations through 2% agarose ethidiumbromide-stained gels revealed that isolations were not free of DNA; however, the relative amount of contaminating DNA was consistent from sample to sample. Thirty-five cycles were performed consisting of 1.25 min at 94°C and 1.5 min at 72°C in a PerkinElmer 480 thermalcycler. All PCRs were terminated after a 10-min extension at 72°C. Secondround PCR was performed using the internally nested primers (BCR-2 and ABL-2) with 1 Ixl of the first-round PCR product as template for an additional 35 cycles. The sequences of the oligonucleotide primers BCR-I, BCR-2, ABL-1, ABL-2, and ABL-3 have been previously described [2] . A total of 15 txl of each amplified PCR product was analyzed by electrophoresis through 2% agarose gels and stained with ethidium bromide.
Reverse Transcription and PCR
Assay Control
Specific measures to ensure accurate results in routine testing were incorporated into this assay. All RNA isolations, cDNA synthesis, and all setups (except for introduction of second-round PCR template) were performed in a positive pressure high-efficiency particulate air (HEPA)-filtered clean room to prevent the introduction of previously amplified material. The evaluation of RNA integrity and adequate cDNA synthesis from samples was accomplished through the detection of the constitutively expressed ABL mRNA from the same reverse transcription reaction. The ABL cDNA was amplified using the primers ABL-I and ABL-3 (which targets ABL exon la). Assay sensitivity was monitored through the addition and detection of 0.05 ng K562 RNA mixed within a replicate assay for each unknown sample. This RNA quantity represents nucleic acid isolated from -5 K562 cells, which requires two rounds of nested primer PCR for detection. Failure to detect the "spiked" K562 RNA could indicate the presence of inhibitors or ribonucleases within the unknown RNA sample. Mock RNA preparations were included in every assay as negative-control RNA to survey the possibility of false positives due to the introduction of previously amplified DNA. All sample and control RNAs were analyzed in duplicate, beginning with independent RNA isolations.
Results and Discussion
Assay Sensitivity 
Assay Validation
A validation study of 82 samples was performed using 25 prepared dilutions of K562 cells into normal cultured B cells, 26 pre-and posttransplant peripheral blood samples from CML patients, 16 peripheral blood samples for diagnosis of CML, and 15 peripheral blood samples from healthy individuals. Samples were tested in duplicate, with both the ABL positive control and "spiked" K562 positive control; additionally, negative-control samples were included with every assay. The results of this study are provided in Table 1 . Dilutions of K562 cells (106, 103, 10, and 1) mixed with 3 x 10 6 normal cultured B cells were prepared and tested in a blind manner. The presence of 10 6 and 10 3 K562 cells admixed with 3 x 10 6 normal cultured B cells was detected always in the first and second rounds of PCR. Ten K562 cells admixed with 3 x 10 6 normal cultured B cells always required two rounds of PCR for detection. One K562 cell admixed with 3 x 106 normal cultured B cells was detected after two rounds of PCR 2/5 times. The bcr/abl oncogene message was never detected in the samples that contained no K562 cells or negative controls. Samples from 26 pre-and post-BMT patients were assayed for Phi by nested primer PCR at the Blood Center of Southeastern Wisconsin; these samples had also been previously assayed at an independent institution under similar but not identical conditions. A concordance rate of 85% (22 samples of 26 patients) was seen within this sample subset; all four discrepancies (two positive and two negative) were in the second round of PCR. When these four samples were previously tested, RNA template was not quantified; therefore, an unknown amount of RNA was surveyed. In assays performed at the Blood Center of Southeastern Wisconsin, however, RNA isolations were quantified, with 1 Ixg of starting nucleic acid always added into reverse transcription reactions. Although nucleic acid isolations at both institutions were similar, the observed discrepancies in this sample subset may have been due to differences in the quantity of RNA surveyed. It is also expected that some assay variability will exist when samples that possess numbers of Phi-positive cells near the threshold level of detection are tested. This variability is partly controlled by duplicate testing of all samples from independent RNA isolations. Sixteen pretreatment/transplant peripheral blood samples were provided for analysis by local hematologists and oncologists. In all 16 cases, there was 100% concordance between the molecular analysis by nested primer RT-PCR and cytogenetic analysis. In addition, a random selection of 15 healthy blood donor samples were assayed for the presence of Phi. All samples were negative for BCR/ABL and positive for ABL, as expected; all K562 positive control samples indicated the predicted sensitivity. These results are also summarized in Table 1 .
Representative analysis of clinical samples is shown in Figure 3 
Conclusions.
Internally, this assay was 100% reproducible; an overall concordance rate of/>95% was observed with other measurements (dilution studies, molecular analysis, cytogenetic analysis). Sensitivity was monitored in every assay. Assay components (enzymes, primers, buffers) were also internally controlled in each assay. Contamination of samples was monitored by duplicate sample analysis and by the inclusion of blank samples in each assay. This approach provides a very sensitive, reproducible, and rapid assay for the presence of Phi-positive cells, which has utility not only for detection of minimal residual disease after treatment but as a tool for establishing a diagnosis of CML. More important, the steps outlined here for assay control can be adaptable to any PCR-based detection scheme.
This work was supported in part byR29DK43470 from the National Institutes of Health, Bethesda, MD. We thank the members of the greater Milwaukee hematology/oncology community for the referral of samples and for sharing with us the results of the corresponding cytogenetic analysis. We are also grateful to Daniel Bellissimo, PhD, for preparing the cells for blind analysis.
